Biothera Inc., of Eagan, Minn., reported the results of its Phase II trial evaluating the effectiveness of Imprime PGG in combination with Erbitux (cetuximab), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapies alone in previously untreated patients with advanced non-small-cell lung cancer.